In vitro human tissue models in risk assessment: report of a consensus-building workshop.

Advances in the technology of human cell and tissue culture and the increasing availability of human tissue for laboratory studies have led to the increased use of in vitro human tissue models in toxicology and pharmacodynamics studies and in quantitative modeling of metabolism, pharmacokinetic behavior, and transport. In recognition of the potential importance of such models in toxicological risk assessment, the Society of Toxicology sponsored a workshop to evaluate the current status of human cell and tissue models and to develop consensus recommendations on the use of such models to improve the scientific basis of risk assessment. This report summarizes the evaluation by invited experts and workshop attendees of the current status of such models for prediction of human metabolism and identification of drug-drug interactions, prediction of human toxicities, and quantitative modeling of pharmacokinetic and pharmaco-toxicodynamic behavior. Consensus recommendations for the application and improvement of current models are presented.

[1]  S. Ekins,et al.  The role of CYP2B6 in human xenobiotic metabolism. , 1999, Drug metabolism reviews.

[2]  J. Houston,et al.  Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[3]  L. J. Fischer,et al.  Hamster hepatocytes in culture as a model for acetaminophen toxicity studies with inhibitors of drug metabolism. , 1983, Toxicology and applied pharmacology.

[4]  H. Kusuhara,et al.  The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. , 1998, Journal of pharmaceutical sciences.

[5]  E. Gillam.  HUMAN CYTOCHROME P450 ENZYMES EXPRESSED IN BACTERIA: REAGENTS TO PROBE MOLECULAR INTERACTIONS IN TOXICOLOGY , 1998, Clinical and experimental pharmacology & physiology.

[6]  G. L. Kedderis,et al.  Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. , 1996, Toxicology and applied pharmacology.

[7]  J. Houston,et al.  Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[8]  P. Watkins,et al.  First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. , 1999, The Journal of pharmacology and experimental therapeutics.

[9]  B. Ames.  Cancer prevention and diet: help from single nucleotide polymorphisms. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  G. L. Kedderis,et al.  Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. , 1999, Chemico-biological interactions.

[11]  P. Olinga,et al.  Liver slices in in vitro pharmacotoxicology with special reference to the use of human liver tissue. , 1997, Toxicology in vitro : an international journal published in association with BIBRA.

[12]  B. Ring,et al.  The Use of In Vitro Metabolism Techniques in the Planning and Interpretation of Drug Safety Studies , 1995, Toxicologic pathology.

[13]  John H. Draize,et al.  METHODS FOR THE STUDY OF IRRITATION AND TOXICITY OF SUBSTANCES APPLIED TOPICALLY TO THE SKIN AND MUCOUS MEMBRANES , 1944 .

[14]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[15]  Division on Earth.  Risk Assessment in the Federal Government: Managing the Process , 1983 .

[16]  R. Parchment,et al.  Haematotoxicity of mycotoxins , 1998 .

[17]  C. Jamis-Dow,et al.  Glucuronidation of 3′-Azido-3′-Deoxythymidine (Zidovudine) by Human Liver Microsomes: Relevance to Clinical Pharmacokinetic Interactions with Atovaquone, Fluconazole, Methadone, and Valproic Acid , 1998, Antimicrobial Agents and Chemotherapy.

[18]  R. Parchment,et al.  Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro , 1997, Cancer Chemotherapy and Pharmacology.

[19]  Y. Fujii‐Kuriyama,et al.  Identification of a meander region proline residue critical for heme binding to cytochrome P450: implications for the catalytic function of human CYP4B1. , 1998, Biochemistry.

[20]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[21]  A. Vickers.  5 – Experimental In Vitro Models to Evaluate Hepatotoxicity , 1996 .

[22]  R. Ulrich,et al.  Disruption of mitochondrial activities in rabbit and human hepatocytes by a quinoxalinone anxiolytic and its carboxylic acid metabolite. , 1998, Toxicology.

[23]  H. Bartsch,et al.  Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  M L Gargas,et al.  Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro. , 1993, Toxicology and applied pharmacology.

[25]  J. Houston,et al.  Sigmoidal Kinetics of CYP 3 A Substrates : An Approach for Scaling Dextromethorphan Metabolism in Hepatic Microsomes and Isolated Hepatocytes to Predict In Vivo Clearance in Rat 1 , 1999 .

[26]  Steven D. Cohen,et al.  Acetaminophen hepatotoxicity: correspondence of selective protein arylation in human and mouse liver in vitro, in culture, and in vivo. , 1990, Toxicology and applied pharmacology.

[27]  M Liebsch,et al.  Eye Irritation Testing: The Way Forward. The Report and Recommendations of ECVAM Workshop 34. , 1999, Alternatives to laboratory animals : ATLA.

[28]  J B Houston,et al.  Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.

[29]  M A Perkins,et al.  Development and intralaboratory evaluation of an in vitro human cell-based test to aid ocular irritancy assessments. , 1995, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[30]  J. J. van de Sandt,et al.  Alternative Methods for Skin Irritation Testing: The Current Status , 1998, Alternatives to laboratory animals : ATLA.

[31]  A. Vickers,et al.  Changes in human liver and kidney slice function related to potential side-effects in the presence of biotransformation of four cyclosporin derivatives : CSA, IMM, OG, and PSC , 1998 .

[32]  P. H. Bach,et al.  The Use of Tissue Slices for Pharmacotoxicology Studies , 1996 .

[33]  H. Glatt,et al.  Sulfotransferases: genetics and role in toxicology. , 2000, Toxicology letters.

[34]  J. Tredger,et al.  Induction of CYP3A isoforms in cultured precision-cut human liver slices. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[35]  M D Todd,et al.  Emerging technologies for accelerated toxicity evaluation of potential drug candidates. , 1999, Current opinion in drug discovery & development.

[36]  T. Yoshida,et al.  Endotoxin‐induced cytokine gene expression and excretion in the liver , 1994, Hepatology.

[37]  J. Strong,et al.  Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation. , 1997, The Journal of pharmacology and experimental therapeutics.

[38]  R Roguet,et al.  The use of in vitro reconstituted human skin in dermotoxicity testing. , 1994, Toxicology in vitro : an international journal published in association with BIBRA.

[39]  C S Weil,et al.  Study of intra- and interlaboratory variability in the results of rabbit eye and skin irritation tests. , 1971, Toxicology and applied pharmacology.

[40]  G. L. Kedderis,et al.  Furan-induced cytolethality in isolated rat hepatocytes: correspondence with in vivo dosimetry. , 1993, Toxicology and applied pharmacology.

[41]  J. Houston,et al.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. , 1999, British journal of clinical pharmacology.

[42]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[43]  F. Kadlubar,et al.  Human cytochrome P4501A2. , 1999, IARC scientific publications.

[44]  J. Tredger,et al.  Inhibition of xenobiotic-induced genotoxicity in cultured precision-cut human and rat liver slices. , 1999, Mutation research.

[45]  M. Murray,et al.  Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. , 1999, Biochemical pharmacology.

[46]  M. Ghielmini,et al.  Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  G. L. Kedderis.  Extrapolation of in vitro enzyme induction data to humans in vivo. , 1997, Chemico-biological interactions.

[48]  E. Walum,et al.  13th Meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals (SGOMSEC): validation and acute toxicity testing. , 1998, Environmental health perspectives.

[49]  R. Parchment,et al.  Roles for In Vitro Myelotoxicity Tests in Preclinical Drug Development and Clinical Trial Planning , 1993, Toxicologic pathology.

[50]  Rosemarie Osborne,et al.  Development and Intralaboratory Evaluation of an in Vitro Human Cell-Based Test to Aid Ocular Irritancy Assessments , 1995 .

[51]  G. Kearns,et al.  Cytochrome P450 3A , 1999, Clinical pharmacokinetics.

[52]  K. Tsai,et al.  NAD(P)H: quinone oxidoreductase polymorphism and lung cancer in Taiwan. , 1999, Journal of toxicology and environmental health. Part A.

[53]  E. Ford,et al.  Genetic polymorphism , 2020, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[54]  P. Vineis,et al.  Scientific and ethical aspects of genetic screening of workers for cancer risk: the case of the N-acetyltransferase phenotype. , 1995, Journal of clinical epidemiology.

[55]  A. Li,et al.  Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. , 1999, Chemico-biological interactions.

[56]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[57]  M. Doll,et al.  Molecular Genetics and Epidemiology of the NAT 1 and NAT 2 Acetylation Polymorphisms 1 , 2000 .

[58]  G. Carr,et al.  The Performance of the Tissue Equivalent Assay using the Skin(2)(TM) ZK1200 Model in the COLIPA International Validation Study on Alternatives to the Draize Eye Irritation Test. , 1999, Toxicology in vitro : an international journal published in association with BIBRA.

[59]  P. Seglen.  Preparation of isolated rat liver cells. , 1976, Methods in cell biology.

[60]  P. Watkins,et al.  Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. , 1997, Molecular pharmacology.

[61]  M. E. Fitzsimmons,et al.  Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[62]  M E Andersen,et al.  Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.

[63]  B. Burchell,et al.  Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases. , 2000, Toxicology letters.

[64]  T Iwatsubo,et al.  PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.

[65]  M. Bayliss,et al.  Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[66]  H. Schaefer,et al.  Overview of in vitro cell culture technologies and pharmaco-toxicological applications. , 1997, Toxicology in vitro : an international journal published in association with BIBRA.

[67]  H F Li,et al.  Confocal microscopic characterization of initial corneal changes of surfactant-induced eye irritation in the rabbit. , 1997, Toxicology and applied pharmacology.

[68]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[69]  R. Parchment,et al.  In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow. , 1994, Journal of the National Cancer Institute.

[70]  Ortiz de Montellano,et al.  Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .

[71]  R. Esterline,et al.  Metabolic alterations resulting from the inhibition of mitochondrial respiration by acetaminophen in vivo. , 1989, Biochemical pharmacology.

[72]  D. Acosta,et al.  IRAG working group 4: Cell cytotoxicity assays , 1997 .

[73]  G. Diggle,et al.  Science and Judgement in Risk Assessment , 1995 .

[74]  Albert P. Li,et al.  Isolation and culturing of hepatocytes from human livers , 1992 .

[75]  K. H. Lee,et al.  Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population. , 2000, Pharmacogenetics.

[76]  R. Ulrich,et al.  A protocol for isolation, culture, and cryopreservation of hepatocytes from human liver , 1998 .

[77]  R. Ulrich,et al.  Cultured hepatocytes as investigational models for hepatic toxicity: practical applications in drug discovery and development. , 1995, Toxicology letters.

[78]  H Spielmann,et al.  The EC/HO international validation study on alternatives to the draize eye irritation test. , 1995, Toxicology in vitro : an international journal published in association with BIBRA.

[79]  G. L. Kedderis,et al.  Chloroform-induced cytolethality in freshly isolated male B6C3F1 mouse and F-344 rat hepatocytes. , 1998, Toxicology and applied pharmacology.

[80]  M. Doll,et al.  Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[81]  Roger G. Ulrich,et al.  An in Vitro Fluorescence Assay for the Detection of Drug-Induced Cytoplasmic Lamellar Bodies , 1991 .

[82]  L. Dipasquale,et al.  Evaluation of a human corneal epithelial cell line as an in vitro model for assessing ocular irritation. , 1997, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[83]  T. Yoshida,et al.  Role of tumor necrosis factor-alpha in cadmium-induced hepatotoxicity. , 1995, Toxicology and applied pharmacology.

[84]  M. Wang,et al.  Effective cryopreservation and long-term storage of primary human hepatocytes with recovery of viability, differentiation, and replicative potential. , 1995, Cell transplantation.

[85]  R. Parchment.  Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity. , 1998, Environmental health perspectives.

[86]  G. Trainor,et al.  Preclinical antitumor activity of XK469 (NSC 656889) , 1998, Investigational New Drugs.

[87]  A. Li,et al.  Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. , 1997, Chemico-biological interactions.

[88]  V. Hosagrahara,et al.  Epoxide hydrolase--polymorphism and role in toxicology. , 2000, Toxicology letters.

[89]  M E Andersen,et al.  Physiological modelling of organic compounds. , 1991, The Annals of occupational hygiene.

[90]  Y. Sugiyama,et al.  Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.

[91]  M. Ingelman-Sundberg,et al.  Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. , 2000, Pharmacogenetics.

[92]  T. Daemen,et al.  Cells of the hepatic sinusoid , 1989 .

[93]  Y. Sugiyama,et al.  Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamics. , 1995, Cancer treatment reviews.

[94]  D. Eaton,et al.  Concise review of the glutathione S-transferases and their significance to toxicology. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[95]  B. Kennedy,et al.  Refinement of an in vitro cell model for cytochrome P450 induction. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[96]  S. Strom,et al.  Use of human hepatocytes to study P450 gene induction. , 1996, Methods in enzymology.